Inhibition of multidrug resistance protein 1 (MRP1) improves chemotherapy drug response in primary and recurrent glioblastoma multiforme

Glioblastoma multiforme (GBM) is a highly aggressive brain cancer with extremely poor prognostic outcome despite intensive treatment. All chemotherapeutic agents currently used have no greater than 30–40% response rate, many fall into the range of 10–20%, with delivery across the blood brain barrier...

Descripción completa

Detalles Bibliográficos
Autores principales: Tivnan, Amanda, Zakaria, Zaitun, O'Leary, Caitrín, Kögel, Donat, Pokorny, Jenny L., Sarkaria, Jann N., Prehn, Jochen H. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468867/
https://www.ncbi.nlm.nih.gov/pubmed/26136652
http://dx.doi.org/10.3389/fnins.2015.00218

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468867/
https://www.ncbi.nlm.nih.gov/pubmed/26136652
http://dx.doi.org/10.3389/fnins.2015.00218

Ejemplares similares